Cystic Fibrosis (CF) occurs 1 in 3,000 newborns and affects more than 100,000 individuals worldwide.CF is a genetic disease that mainly affects the digestive system and the lungs. In the lungs, CF causes the production of thick mucus in the airways. This thick mucus blocks the airways and makes those living with CF more prone to bacterial infections. Treating these infections requires antibiotics, and often those on repeated courses of antibiotics can become antibiotic resistant and therefor not as effective.
In his project titled Peptide Therapeutics for Cystic Fibrosis, principle investigator Dr. Mohan Babu from the University of Regina will be studying new antibacterial therapies needed to treat CF patients that suffer from lung infections.
Hope for the Future
It is the hope of Dr. Babu and his team that this research will help identify new drug therapies for CF patients in Saskatchewan and Canadians at large.